Product Information
ERYPED 400 MG/5 ML SUSPENSION is a brand product labeled by Carnegie Pharmaceuticals LLC, priced at $6.3072 per ML under NDC 80005015518. Its NADAC has been published 41 times since Apr 9, 2025.
Strength
400 mg/5mL
Manufacturer
Carnegie Pharmaceuticals LLCNDC
80005015518
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Last Updated
4/9/2025
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA050207On Market Since
1/15/2025
Pharmacological Classes
Price Statistics
The NADAC for ERYPED 400 MG/5 ML SUSPENSION has been published 41 times since Apr 9, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.3072 per ML |
|---|---|
| All-time high | $6.3072 (Jan 14, 2026) |
| All-time low | $6.3072 (Apr 9, 2025) |
| 52-week high | $6.3072 |
| 52-week low | $6.3072 |
| Median price | $6.3072 |
| Average price | $6.3072 |
| Largest weekly change | 0.0% (Apr 16, 2025) |
| Weeks tracked | 41 |
| Tracking since | Apr 9, 2025 |
Generic Alternatives
The matcher finds 4 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 4 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 72% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ERYPED 400 MG/5 ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for ERYPED 400 MG/5 ML SUSPENSION, manufactured by Carnegie Pharmaceuticals LLC, is $6.3072 per ML (NDC 80005015518), effective Jan 14, 2026.
How has the price of ERYPED 400 MG/5 ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for ERYPED 400 MG/5 ML SUSPENSION has held within roughly two percent of its current level. It has been tracked across 41 weekly CMS publications since Apr 9, 2025.
What are the highest and lowest recorded NADAC prices for ERYPED 400 MG/5 ML SUSPENSION?
Since Apr 9, 2025, the NADAC for ERYPED 400 MG/5 ML SUSPENSION has ranged from a low of $6.3072 (Apr 9, 2025) to a high of $6.3072 (Jan 14, 2026), with a median of $6.3072 per ML.
Are there cheaper alternatives to ERYPED 400 MG/5 ML SUSPENSION?
Yes. 4 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, ERYTHROMYCIN 400 MG/5 ML SUSP, is $1.7573 per ML — about 72% below ERYPED 400 MG/5 ML SUSPENSION.
Who manufactures ERYPED 400 MG/5 ML SUSPENSION?
ERYPED 400 MG/5 ML SUSPENSION (NDC 80005015518) is labeled by Carnegie Pharmaceuticals LLC, and CMS classifies it as a brand product.
Related Drugs
Same classification